Advertisement
Canada markets open in 5 hours 42 minutes
  • S&P/TSX

    22,373.38
    +52.51 (+0.24%)
     
  • S&P 500

    5,304.72
    +36.88 (+0.70%)
     
  • DOW

    39,069.59
    +4.29 (+0.01%)
     
  • CAD/USD

    0.7340
    +0.0004 (+0.05%)
     
  • CRUDE OIL

    78.74
    +1.02 (+1.31%)
     
  • Bitcoin CAD

    92,319.57
    -1,217.01 (-1.30%)
     
  • CMC Crypto 200

    1,473.46
    -23.00 (-1.54%)
     
  • GOLD FUTURES

    2,344.80
    +10.30 (+0.44%)
     
  • RUSSELL 2000

    2,069.67
    +21.26 (+1.04%)
     
  • 10-Yr Bond

    4.4670
    0.0000 (0.00%)
     
  • NASDAQ futures

    18,926.00
    +50.00 (+0.26%)
     
  • VOLATILITY

    12.50
    +0.14 (+1.13%)
     
  • FTSE

    8,309.05
    -8.54 (-0.10%)
     
  • NIKKEI 225

    38,855.37
    -44.65 (-0.11%)
     
  • CAD/EUR

    0.6745
    -0.0007 (-0.10%)
     

DIAGNOS Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS In Line

DIAGNOS (CVE:ADK) Third Quarter 2024 Results

Key Financial Results

  • Revenue: CA$52.1k (down 57% from 3Q 2023).

  • Net loss: CA$810.0k (loss widened by 58% from 3Q 2023).

  • CA$0.011 loss per share (further deteriorated from CA$0.007 loss in 3Q 2023).

earnings-and-revenue-history
earnings-and-revenue-history

All figures shown in the chart above are for the trailing 12 month (TTM) period

DIAGNOS Earnings Insights

Looking ahead, revenue is forecast to grow 222% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Healthcare Services industry in North America.

Performance of the market in Canada.

The company's shares are down 5.2% from a week ago.

Risk Analysis

You should learn about the 6 warning signs we've spotted with DIAGNOS (including 3 which can't be ignored).

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.